Firms Vow To Appeal After CMA’s £260m Hydrocortisone Fines In UK
Accord, Advanz And Waymade Respond To Decision By Competition Regulator
Firms censured by the UK’s CMA competition regulator over illegal deals that drove up the price of hydrocortisone for around a decade have vowed to appeal against the decision and the imposition of fines totaling more than £260m.
You may also be interested in...
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
Fines imposed on firms including Actavis, Alpharma, Generics UK and Xellia as well as GlaxoSmithKline have been reduced following Competition Appeal Tribunal ruling that nevertheless upheld a finding of competition law infringement linked to historical pay-for-delay deals.
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.